Skip to main navigation Skip to search Skip to main content

The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics

  • Hélène G. Bazin
  • , Tim J. Murray
  • , William S. Bowen
  • , Afsaneh Mozaffarian
  • , Steven P. Fling
  • , Laura S. Bess
  • , Mark T. Livesay
  • , Jeffrey S. Arnold
  • , Craig L. Johnson
  • , Kendal T. Ryter
  • , Christopher W. Cluff
  • , Jay T. Evans
  • , David A. Johnson

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

To overcome the chemical and metabolic instability of the secondary fatty acyl residues in the AGP class of lipid A mimetics, the secondary ether lipid analogs of the potent TLR4 agonist CRX-527 (2) and TLR4 antagonist CRX-526 (3) were synthesized and evaluated along with their ester counterparts for agonist/antagonist activity in both in vitro and in vivo models. Like CRX-527, the secondary ether lipid 4 showed potent agonist activity in both murine and human models. Ether lipid 5, on the other hand, showed potent TLR4 antagonist activity similar to CRX-526 in human cell assays, but did not display any antagonist activity in murine models and, in fact, was weakly agonistic. Glycolipids 2, 4, and 5 were synthesized via a new highly convergent method utilizing a common advanced intermediate strategy. A new method for preparing (R)-3-alkyloxytetradecanoic acids, a key component of ether lipids 4 and 5, is also described.

Original languageEnglish
Pages (from-to)5350-5354
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number20
DOIs
StatePublished - Oct 15 2008

Keywords

  • AGP
  • Glycolipids
  • Immunostimulants
  • Lipid A mimetics
  • Reductive alkylation
  • TLR4 agonist
  • TLR4 antagonist

Fingerprint

Dive into the research topics of 'The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics'. Together they form a unique fingerprint.

Cite this